Characterization of Novel Dengue Antibody Derived from Vaccination
Conference Year
2023
Abstract
Dengue virus is part of the family Flaviviridae and infects about 50-200 million people annually. There are four disease-causing serotypes, so it is imperative that a vaccine elicits a strong response to all four. Currently, a live attenuated tetravalent dengue vaccine (TV003) has appeared effective in clinical trials, but it is unclear whether the immune response is type-specific or cross-reactive. To investigate this question, my experiment involved isolating a dengue-specific monoclonal antibody from a TV003 recipient and analyzing its characteristics. Determining the characteristics of this antibody would allow researchers to understand the specific response the vaccine generated.
Primary Faculty Mentor Name
Sean Diehl
Graduate Student Mentors
Camilla Strother
Status
Undergraduate
Student College
College of Agriculture and Life Sciences
Program/Major
Molecular Genetics
Primary Research Category
Clinical
Characterization of Novel Dengue Antibody Derived from Vaccination
Dengue virus is part of the family Flaviviridae and infects about 50-200 million people annually. There are four disease-causing serotypes, so it is imperative that a vaccine elicits a strong response to all four. Currently, a live attenuated tetravalent dengue vaccine (TV003) has appeared effective in clinical trials, but it is unclear whether the immune response is type-specific or cross-reactive. To investigate this question, my experiment involved isolating a dengue-specific monoclonal antibody from a TV003 recipient and analyzing its characteristics. Determining the characteristics of this antibody would allow researchers to understand the specific response the vaccine generated.